You are here: Industry Insights > STORM CHASER

News List

STORM CHASER Trial Fails to Meet Primary Endpoint in Post-Exposure Prevention of Symptomatic COVID-19 americanpharmaceuticalreview
June 17, 2021
AstraZeneca announced results from the STORM CHASER trial assessing the safety and efficacy of AZD7442, a long-acting antibody (LAAB) combination, for the prevention of symptomatic COVID-19 in participants recently exposed to the SARS-CoV-2 virus.
Matrix Collaborates with AstraZeneca on Trial for COVID-19 Long-Acting Antibody Combination americanpharmaceuticalreview
February 09, 2021
Matrix Medical Network® announced a collaboration with AstraZeneca to accelerate a clinical trial in the US for AZD7442, AstraZeneca's long-acting monoclonal antibody (LAAB) combination for the potential prevention of COVID-19.
Care Access Research, AstraZeneca Partner on COVID-19 Antibody Trial contractpharma
January 27, 2021
Care Access to provide decentralized, mobile research site operations for AstraZeneca’s AZD7442 Phase III trial in the U.S.